so, I'll make it pure for you, and allocate the 0.3X cash........
in the context of $200M, an established research infrastructure, an experienced regulatory group, additional assets, and the slew of lawsuits..........
RSV program, and time on the learning curve, small molecules delivered via inhalation...... $35M.
HCV program, post 50406 and given that (1) phase I for the second molecule is targeted 2H02, and (2) the Wyeth/VPHM program is aiming for depth and breadth...... $100M.
I presume that's pure enough? If so, please criticize. Is it leveraged? If so, how long would it take for the leverage to come apart, given a lack of visible progress? TIA for any comments. |
